Literature DB >> 28870001

An efficient new method for the synthesis of 3-[18 F]fluoro-4-aminopyridine via Yamada-Curtius rearrangement.

Falguni Basuli1, Xiang Zhang1, Pedro Brugarolas2, Daniel S Reich3, Rolf E Swenson1.   

Abstract

4-Aminopyridine is a clinically approved drug to improve motor symptoms in multiple sclerosis. A fluorine-18-labeled derivative of this drug, 3-[18 F]fluoro-4-aminopyridine, is currently under investigation for positron emission tomography (PET) imaging of demyelination. Herein, the Yamada-Curtius reaction has been successfully applied for the preparation of this PET radioligand with a better radiochemical yield and improved specific activity. The overall radiochemical yield was 5 to 15% (n = 12, uncorrected) with a specific activity of 37 to 148 GBq/μmol (end of synthesis) in a 90 minute synthesis time. It is expected that this 1 pot Yamada-Curtius reaction can be used to prepare similar fluorine-18-labeled amino substituted heterocycles. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  F-18; PET; Yamada-Curtius rearrangement; aminopyridine; multiple sclerosis

Mesh:

Substances:

Year:  2017        PMID: 28870001      PMCID: PMC5992582          DOI: 10.1002/jlcr.3560

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  8 in total

1.  Selective syntheses of no-carrier-added 2- and 3-[18F]fluorohalopyridines through the radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates.

Authors:  Joong-Hyun Chun; Victor W Pike
Journal:  Chem Commun (Camb)       Date:  2012-08-30       Impact factor: 6.222

Review 2.  (18)F-Labeling of Arenes and Heteroarenes for Applications in Positron Emission Tomography.

Authors:  Sean Preshlock; Matthew Tredwell; Véronique Gouverneur
Journal:  Chem Rev       Date:  2016-01-11       Impact factor: 60.622

Review 3.  Fluorine-18-labelled fluoropyridines: advances in radiopharmaceutical design.

Authors:  F Dollé
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

Review 4.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

Review 5.  Roles of Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents.

Authors:  Supaluk Prachayasittikul; Ratchanok Pingaew; Apilak Worachartcheewan; Nujarin Sinthupoom; Veda Prachayasittikul; Somsak Ruchirawat; Virapong Prachayasittikul
Journal:  Mini Rev Med Chem       Date:  2017       Impact factor: 3.862

6.  A simple synthetic route to methyl 3-fluoropyridine-4-carboxylate by nucleophilic aromatic substitution.

Authors:  Freddy Tjosaas; Anne Fiksdahl
Journal:  Molecules       Date:  2006-02-25       Impact factor: 4.411

7.  Rapid microfluidic flow hydrogenation for reduction or deprotection of 18F-labeled compounds.

Authors:  Steven H Liang; Thomas Lee Collier; Benjamin H Rotstein; Rebecca Lewis; Mia Steck; Neil Vasdev
Journal:  Chem Commun (Camb)       Date:  2013-10-09       Impact factor: 6.222

8.  Synthesis of meta-substituted [(18)F]3-fluoro-4-aminopyridine via direct radiofluorination of pyridine N-oxides.

Authors:  P Brugarolas; R Freifelder; S-H Cheng; O DeJesus
Journal:  Chem Commun (Camb)       Date:  2016-05-12       Impact factor: 6.222

  8 in total
  8 in total

1.  Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for demyelinating diseases.

Authors:  Karla M Ramos-Torres; Yu-Peng Zhou; Bo Yeun Yang; Nicolas J Guehl; Moon Sung-Hyun; Sanjay Telu; Marc D Normandin; Victor W Pike; Pedro Brugarolas
Journal:  RSC Med Chem       Date:  2020-07-24

2.  Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP.

Authors:  Pedro Brugarolas; Moses Q Wilks; Jacqueline Noel; Julia-Ann Kaiser; Danielle R Vesper; Karla M Ramos-Torres; Nicolas J Guehl; Marina T Macdonald-Soccorso; Yang Sun; Peter A Rice; Daniel L Yokell; Ruth Lim; Marc D Normandin; Georges El Fakhri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10-05       Impact factor: 10.057

3.  NRM 2021 Abstract Booklet.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2021-12       Impact factor: 6.960

4.  Radiochemical Synthesis and Evaluation in Non-Human Primates of 3-[11C]methoxy-4-aminopyridine: A Novel PET Tracer for Imaging Potassium Channels in the CNS.

Authors:  Nicolas J Guehl; Ramesh Neelamegam; Yu-Peng Zhou; Sung-Hyun Moon; Maeva Dhaynaut; Georges El Fakhri; Marc D Normandin; Pedro Brugarolas
Journal:  ACS Chem Neurosci       Date:  2021-02-04       Impact factor: 4.418

5.  Development of a PET radioligand for potassium channels to image CNS demyelination.

Authors:  Pedro Brugarolas; Jorge E Sánchez-Rodríguez; Hsiu-Ming Tsai; Falguni Basuli; Shih-Hsun Cheng; Xiang Zhang; Andrew V Caprariello; Jerome J Lacroix; Richard Freifelder; Dhanabalan Murali; Onofre DeJesus; Robert H Miller; Rolf E Swenson; Chin-Tu Chen; Peter Herscovitch; Daniel S Reich; Francisco Bezanilla; Brian Popko
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

6.  Detecting Demyelination by PET: The Lesion as Imaging Target.

Authors:  Pedro Brugarolas; Daniel S Reich; Brian Popko
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

7.  Structure-activity relationship studies of four novel 4-aminopyridine K+ channel blockers.

Authors:  Sofia Rodríguez-Rangel; Alyssa D Bravin; Karla M Ramos-Torres; Pedro Brugarolas; Jorge E Sánchez-Rodríguez
Journal:  Sci Rep       Date:  2020-01-09       Impact factor: 4.379

8.  Evaluation of the potassium channel tracer [18F]3F4AP in rhesus macaques.

Authors:  Nicolas J Guehl; Karla M Ramos-Torres; Clas Linnman; Sung-Hyun Moon; Maeva Dhaynaut; Moses Q Wilks; Paul K Han; Chao Ma; Ramesh Neelamegam; Yu-Peng Zhou; Brian Popko; John A Correia; Daniel S Reich; Georges El Fakhri; Peter Herscovitch; Marc D Normandin; Pedro Brugarolas
Journal:  J Cereb Blood Flow Metab       Date:  2020-10-22       Impact factor: 6.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.